SANA · Sana Biotechnology, Inc.
$3.85
-0.07 (-1.79%)
At close · Sep 4
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that our present capital resources may not be sufficient to fund our planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$1.17B
Shares
299.36M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.85
Open$3.86
Day$3.81–3.92
52W close$2.68–5.92
Avg vol 30d2.5M
Short int42.6M · 14.2% float · 18.0d
Short vol46%
Last earningsMay 8, 2025
DataFeb 2021–Sep 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$211.82M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$160.49M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+24.0%
Year over year · more shares
Price change (1Y)
+29.2%
Trailing year
Short interest
14.2%
Latest settlement · 18.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
+7%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
36%
mid-range
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+18%
trailing
YTD return
−5%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.22% of float · ▲ +1.0% MoM · 18.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
215 holders — near 3-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
EPS growth
+17%
Y/Y
Free cash flow
$-144.8M
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the 8-K filed Aug 8, 2024
Operating cash burn
· 2024
up to $200M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
36%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.22% of float · ▲ +1.0% MoM · 18.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
215 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $4 · 36%
Range high $6
vs 200-day avg +4%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SANA
this stock
Sana Biotechnology, Inc.
|
$1.17B | -5.4% | — | — | 14.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$141.42B | +20.5% | +46.2% | 32.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.84B | +7.2% | +20.8% | 20.9 | 2.3% |
|
ARGX
Argenx SE
|
$64.44B | +22.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SANA | -2.0% | +9.4% | +17.7% | -0.5% | -5.4% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -2.2% | +9.8% | +2.6% | -0.9% | -18.4% |
Key facts
CIK
1770121
CUSIP
799566104
13F (30d)
165 filings
164 filers
Visit website
Investor relations